ProfileGDS5678 / 1448882_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 85% 84% 84% 84% 81% 84% 85% 86% 84% 83% 84% 85% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0926783
GSM967853U87-EV human glioblastoma xenograft - Control 26.4729685
GSM967854U87-EV human glioblastoma xenograft - Control 36.1569884
GSM967855U87-EV human glioblastoma xenograft - Control 46.385484
GSM967856U87-EV human glioblastoma xenograft - Control 56.2969484
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5755281
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0079384
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3556385
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.4519186
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2391184
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0874983
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2213984
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.3567585
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0713983